We are live on ! Find out more
EBS icon

Emergent Biosolutions

244 hedge funds and large institutions have $2.35B invested in Emergent Biosolutions in 2019 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 89 increasing their positions, 90 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

60% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 20

6% more capital invested

Capital invested by funds: $2.22B → $2.35B (+$135M)

5% more funds holding

Funds holding: 233244 (+11)

1% less repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 90

2.1% less ownership

Funds ownership: 89.26%87.16% (-2.1%)

87% less call options, than puts

Call options by funds: $371K | Put options by funds: $2.75M

Holders
244
Holders Change
+11
Holders Change %
+4.72%
% of All Funds
5.35%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
32
Increased
89
Reduced
90
Closed
20
Calls
$371K
Puts
$2.75M
Net Calls
-$2.38M
Net Calls Change
-$2.39M

EBS Hedge Fund Activity: Q3 2019 in Review

244 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q3 2019, worth a combined $2.35B — up 6.1% from $2.22B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new EBS positions and 20 closed out — a net gain of 12 holders — while 89 added to existing stakes and 90 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $17.4M. The largest seller was State Street, cutting an estimated $33.3M.

  • 244 institutional investors held Emergent Biosolutions (EBS) as of Q3 2019, up from 233 in Q2 2019.
  • Funds reported $2.35B of Emergent Biosolutions stock for Q3 2019, up 6.1% quarter-over-quarter.
  • 32 funds opened new Emergent Biosolutions positions in Q3 2019 and 20 closed out, a net change of +12 holders.
  • The largest Emergent Biosolutions buyer in Q3 2019 was Millennium Management, an estimated $17.4M added.
  • The largest Emergent Biosolutions seller in Q3 2019 was State Street, an estimated $33.3M sold.

Based on aggregated 13F filings for Q3 2019.